Active mother and daughter

Tarsa Therapeutics is developing an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.  Calcitonin has a long history of safety and efficacy as an osteoporosis therapy but currently is only available in injectable and intranasal formulations. Tarsa’s oral calcitonin tablet has the potential to provide calcitonin’s proven safety and efficacy with the major advantage of once-daily oral dosing. Tarsa’s Phase III clinical trial—the ORACAL study—assessing its oral calcitonin as a treatment for postmenopausal osteoporosis, yielded positive safety and efficacy results, and a Phase II osteoporosis prevention trial is underway.    Learn more »


Osteoporosis is a common but “silent” disease characterized by the loss of bone mass that leads to bone fragility and heightened risk of fractures.  Osteoporosis affects an estimated 75 million people in the US, Europe and Japan and is an important cause of disability and loss of independence worldwide. Learn more >